Short-term exenatide treatment leads to significant weight loss in a subset of obese women without diabetes

What Was Tested

Researchers studied Exenatide and Glucagon in this randomized controlled trial publication.

To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women.

Who Took Part

By PubMed's age tags, the people studied were adults and middle-aged adults, women only.

Forty-one obese women (aged 48 ± 11 years and BMI 33.1 ± 4.1 kg/m(2)) participated in a 35-week randomized, double-blind, placebo-controlled, crossover study, including two 16-week treatment periods separated by a 3-week washout period.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

The participants were allocated by chance, so the Exenatide group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Exenatide.

Some participants received a placebo instead of Exenatide, giving a reference point.

Each person switched between Exenatide and the comparison at some point, usually with a gap in between.

There was no lifestyle intervention.

The primary outcome was change in body weight.

What Was Measured

The subject headings attached to it are Exenatide, Glucagon-Like Peptide-1 Receptor, Hypoglycemic Agents, Nausea, Obesity, Peptides and Receptors, Glucagon.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Exenatide and Glucagon.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2012 (Diabetes care), a journal based in United States.

More context: the Exenatide compound page and the Glucagon compound page.